Moon, C. Y. et al. Dendritic cell maturation in cancer. Nat. Rev. Cancer 25, 225–248 (2025).
You, Q. et al. A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy. Nat. Nanotechnol. 20, 1298–1311 (2025).
Zhou, J. et al. STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity. Nature 643, 519–528 (2025).
Shapir Itai, Y. et al. Bispecific dendritic-T cell engager potentiates anti-tumor immunity. Cell 187, 375–389.e318 (2024).
Eweje, F. et al. Self-assembling protein nanoparticles for cytosolic delivery of nucleic acids and proteins. Nat. Biotechnol. (2025).
Meiser, P. et al. A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. Cancer Cell 41, 1498–1515.e1410 (2023).
Plebanek, M. P. et al. A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression. Sci. Immunol. 9, eadi4191 (2024).
Calzada-Fraile, D. et al. Immune synapse formation promotes lipid peroxidation and MHC-I upregulation in licensed dendritic cells for efficient priming of CD8+T cells. Nat. Commun. 14, 6772 (2023).
Jacobs, C. F. et al. Cholesterol homeostasis and lipid raft dynamics at the basis of tumor-induced immune dysfunction in chronic lymphocytic leukemia. Cell Mol. Immunol. 22, 485–500 (2025).
Lei, K. et al. Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy. Nat. Biomed. Eng. 5, 1411–1425 (2021).
Xiao, J. et al. 25-Hydroxycholesterol regulates lysosome AMP kinase activation and metabolic reprogramming to educate immunosuppressive macrophages. Immunity 57, 1087–1104.e1087 (2024).
Kropshofer, H. et al. Tetraspan microdomains distinct from lipid rafts enrich select peptide-MHC class II complexes. Nat. Immunol. 3, 61–68 (2002).
Geels, S. N. et al. Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy. Cancer Cell 42, 1051–1066.e1057 (2024).
Molino, N. M., Anderson, A. K., Nelson, E. L. & Wang, S. W. Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation. ACS Nano 7, 9743–9752 (2013).
Rosalia, R. A. et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur. J. Immunol. 43, 2554–2565 (2013).
Belabed, M. et al. Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancer. Nat. Immunol. 26, 188–199 (2025).
Li, B. et al. Fueling sentinel node via reshaping cytotoxic T lymphocytes with a flex-patch for post-operative immuno-adjuvant therapy. Nat. Commun. 14, 2518 (2023).
Shapiro, I. E. & Bassani-Sternberg, M. The impact of immunopeptidomics: from basic research to clinical implementation. Semin. Immunol. 66, 101727 (2023).
Zeng, B. et al. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy. J. Clin. Invest. 128, 1971–1984 (2018).
Zhang, J. et al. Stimuli-responsive nanoparticles for controlled drug delivery in synergistic cancer immunotherapy. Adv. Sci. 9, e2103444 (2022).
Cruz, L. J. et al. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: a comparative study. J. Control. Release 192, 209–218 (2014).
